Agios Other Current Assets vs Total Liab Analysis

AGIO Stock

USD 34.79 0.21 0.60%

Agios Pharm financial indicator trend analysis is way more than just evaluating Agios Pharm prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Agios Pharm is a good investment. Please check the relationship between Agios Pharm Other Current Assets and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Other Current Assets vs Total Liab

Other Current Assets vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Agios Pharm Other Current Assets account and Total Liab. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Agios Pharm's Other Current Assets and Total Liab is -0.59. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Total Liab in the same time period over historical financial statements of Agios Pharm, assuming nothing else is changed. The correlation between historical values of Agios Pharm's Other Current Assets and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Agios Pharm are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Other Current Assets i.e., Agios Pharm's Other Current Assets and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.59

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Agios Pharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 1.5 B, while Selling General Administrative is likely to drop about 81.2 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	378.4M	401.6M	408.8M	320.4M
Cost Of Revenue	18.8M	1.7M	9.5M	9.0M

Total Operating Expenses Cost Of Revenue

Agios Pharm fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.73	0.51	0.97	-0.13	0.81	-0.09	0.03	-0.47	0.68	0.12	0.92	-0.15	0.45	0.98	0.89	0.88	0.98	0.26	0.16	0.84	0.33	0.6	0.98	0.0	0.9
Other Current Liab	0.73		0.86	0.56	0.37	0.8	0.15	-0.18	-0.9	0.87	0.33	0.62	-0.36	0.19	0.67	0.84	0.93	0.72	0.68	-0.15	0.95	0.76	0.58	0.73	0.22	0.85
Total Current Liabilities	0.51	0.86		0.33	0.51	0.5	0.48	-0.42	-0.83	0.87	0.53	0.47	-0.33	-0.09	0.46	0.63	0.76	0.51	0.65	-0.12	0.79	0.77	0.34	0.5	0.53	0.65
Total Stockholder Equity	0.97	0.56	0.33		-0.37	0.7	-0.17	0.06	-0.27	0.51	0.07	0.89	-0.1	0.49	0.96	0.83	0.76	0.96	0.0	0.33	0.71	0.07	0.53	0.95	-0.09	0.84
Other Liab	-0.13	0.37	0.51	-0.37		0.09	0.48	-0.32	-0.48	0.41	0.35	-0.15	0.05	-0.4	-0.13	-0.04	0.18	-0.19	0.84	-0.74	0.19	0.82	-0.02	-0.12	0.47	-0.03
Property Plant And Equipment Net	0.81	0.8	0.5	0.7	0.09		-0.33	0.35	-0.7	0.7	-0.19	0.77	-0.49	0.36	0.71	0.8	0.86	0.76	0.56	-0.14	0.86	0.58	0.61	0.79	-0.24	0.82
Current Deferred Revenue	-0.09	0.15	0.48	-0.17	0.48	-0.33		-0.8	-0.02	0.27	0.78	-0.15	0.16	-0.3	-0.02	-0.05	-0.04	-0.07	0.17	0.06	-0.03	0.24	-0.29	-0.06	0.98	-0.04
Net Debt	0.03	-0.18	-0.42	0.06	-0.32	0.35	-0.8		0.05	-0.25	-0.99	0.04	-0.24	0.41	-0.08	0.02	-0.05	0.01	0.0	-0.08	-0.04	-0.09	0.31	0.02	-0.74	0.0
Retained Earnings	-0.47	-0.9	-0.83	-0.27	-0.48	-0.7	-0.02	0.05		-0.79	-0.18	-0.46	0.45	-0.02	-0.37	-0.66	-0.8	-0.45	-0.76	0.34	-0.86	-0.82	-0.52	-0.44	-0.07	-0.68
Accounts Payable	0.68	0.87	0.87	0.51	0.41	0.7	0.27	-0.25	-0.79		0.39	0.71	-0.29	0.01	0.63	0.74	0.86	0.62	0.66	-0.23	0.86	0.74	0.46	0.63	0.31	0.78
Cash	0.12	0.33	0.53	0.07	0.35	-0.19	0.78	-0.99	-0.18	0.39		0.1	0.17	-0.34	0.22	0.13	0.21	0.13	0.1	0.07	0.2	0.19	-0.21	0.12	0.73	0.15
Non Current Assets Total	0.92	0.62	0.47	0.89	-0.15	0.77	-0.15	0.04	-0.46	0.71	0.1		-0.26	0.29	0.89	0.78	0.81	0.83	0.23	0.13	0.79	0.29	0.49	0.83	-0.1	0.82
Non Currrent Assets Other	-0.15	-0.36	-0.33	-0.1	0.05	-0.49	0.16	-0.24	0.45	-0.29	0.17	-0.26		0.14	0.01	-0.23	-0.27	-0.12	-0.18	-0.13	-0.38	-0.22	0.09	-0.09	0.16	-0.24
Other Assets	0.45	0.19	-0.09	0.49	-0.4	0.36	-0.3	0.41	-0.02	0.01	-0.34	0.29	0.14		0.46	0.36	0.29	0.47	-0.06	0.41	0.23	-0.07	0.7	0.5	-0.16	0.34
Cash And Short Term Investments	0.98	0.67	0.46	0.96	-0.13	0.71	-0.02	-0.08	-0.37	0.63	0.22	0.89	0.01	0.46		0.84	0.82	0.95	0.21	0.19	0.76	0.27	0.57	0.97	0.07	0.85
Common Stock Total Equity	0.89	0.84	0.63	0.83	-0.04	0.8	-0.05	0.02	-0.66	0.74	0.13	0.78	-0.23	0.36	0.84		0.89	0.92	0.32	0.07	0.91	0.41	0.67	0.9	0.02	1.0
Common Stock Shares Outstanding	0.88	0.93	0.76	0.76	0.18	0.86	-0.04	-0.05	-0.8	0.86	0.21	0.81	-0.27	0.29	0.82	0.89		0.86	0.55	-0.1	0.98	0.63	0.64	0.86	0.03	0.9
Short Term Investments	0.98	0.72	0.51	0.96	-0.19	0.76	-0.07	0.01	-0.45	0.62	0.13	0.83	-0.12	0.47	0.95	0.92	0.86		0.18	0.21	0.83	0.26	0.6	0.99	0.02	0.92
Non Current Liabilities Total	0.26	0.68	0.65	0.0	0.84	0.56	0.17	0.0	-0.76	0.66	0.1	0.23	-0.18	-0.06	0.21	0.32	0.55	0.18		-0.66	0.55	0.99	0.37	0.26	0.23	0.35
Other Current Assets	0.16	-0.15	-0.12	0.33	-0.74	-0.14	0.06	-0.08	0.34	-0.23	0.07	0.13	-0.13	0.41	0.19	0.07	-0.1	0.21	-0.66		-0.09	-0.59	0.05	0.17	0.12	0.05
Other Stockholder Equity	0.84	0.95	0.79	0.71	0.19	0.86	-0.03	-0.04	-0.86	0.86	0.2	0.79	-0.38	0.23	0.76	0.91	0.98	0.83	0.55	-0.09		0.64	0.62	0.81	0.03	0.92
Total Liab	0.33	0.76	0.77	0.07	0.82	0.58	0.24	-0.09	-0.82	0.74	0.19	0.29	-0.22	-0.07	0.27	0.41	0.63	0.26	0.99	-0.59	0.64		0.39	0.32	0.31	0.43
Property Plant And Equipment Gross	0.6	0.58	0.34	0.53	-0.02	0.61	-0.29	0.31	-0.52	0.46	-0.21	0.49	0.09	0.7	0.57	0.67	0.64	0.6	0.37	0.05	0.62	0.39		0.62	-0.15	0.66
Total Current Assets	0.98	0.73	0.5	0.95	-0.12	0.79	-0.06	0.02	-0.44	0.63	0.12	0.83	-0.09	0.5	0.97	0.9	0.86	0.99	0.26	0.17	0.81	0.32	0.62		0.04	0.89
Short Term Debt	0.0	0.22	0.53	-0.09	0.47	-0.24	0.98	-0.74	-0.07	0.31	0.73	-0.1	0.16	-0.16	0.07	0.02	0.03	0.02	0.23	0.12	0.03	0.31	-0.15	0.04		0.03
Common Stock	0.9	0.85	0.65	0.84	-0.03	0.82	-0.04	0.0	-0.68	0.78	0.15	0.82	-0.24	0.34	0.85	1.0	0.9	0.92	0.35	0.05	0.92	0.43	0.66	0.89	0.03

Click cells to compare fundamentals

Agios Pharm Account Relationship Matchups

Agios Pharm fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	890.7M	853.0M	1.4B	1.2B	937.1M	752.6M
Other Current Liab	53.1M	60.1M	32.0M	30.4M	43.2M	29.6M
Total Current Liabilities	92.9M	94.4M	59.8M	62.6M	68.0M	75.2M
Total Stockholder Equity	640.5M	399.5M	1.3B	1.1B	811.0M	564.7M
Other Liab	77.4M	50.6M	261.3M	3.3M	3.8M	3.6M
Property Plant And Equipment Net	126.1M	117.5M	104.2M	88.1M	69.8M	52.5M
Net Debt	32.7M	(22.2M)	(106.0M)	(53.6M)	(16.2M)	(17.0M)
Retained Earnings	(1.5B)	(1.8B)	(238.8M)	(470.6M)	(822.6M)	(863.8M)
Accounts Payable	21.9M	26.8M	16.7M	18.6M	9.8M	15.9M
Cash	80.9M	127.4M	203.1M	139.3M	88.2M	83.8M
Non Current Assets Total	279.0M	216.3M	373.5M	405.9M	103.3M	178.4M
Non Currrent Assets Other	(279.0M)	1.1M	2.9M	4.0M	4.1M	4.3M
Cash And Short Term Investments	564.9M	670.5M	1.3B	1.1B	776.9M	637.5M
Common Stock Total Equity	58K	68K	69K	71K	81.7K	49.5K
Common Stock Shares Outstanding	60.0M	69.0M	60.4M	54.8M	55.7M	48.8M
Short Term Investments	483.9M	445.5M	816.9M	643.9M	688.7M	428.3M
Liabilities And Stockholders Equity	890.7M	853.0M	1.4B	1.2B	937.1M	752.6M
Non Current Liabilities Total	157.3M	359.1M	85.9M	75.3M	58.1M	112.7M
Other Current Assets	24.2M	(74.0M)	11.8M	39.0M	35.0M	36.8M
Other Stockholder Equity	2.2B	2.2B	1.5B	1.6B	1.6B	1.2B
Total Liab	250.2M	453.5M	145.8M	137.9M	126.1M	187.9M
Property Plant And Equipment Gross	31.5M	117.5M	28.9M	138.2M	122.0M	128.1M
Total Current Assets	611.7M	636.7M	1.1B	832.8M	833.8M	574.2M
Accumulated Other Comprehensive Income	202K	105K	(1.2M)	(12.5M)	(441K)	(463.1K)
Short Term Debt	6.9M	7.4M	11.2M	13.7M	15.0M	27.5M
Common Stock	58K	68K	69K	71K	72K	51.8K
Property Plant Equipment	31.5M	32.3M	28.9M	23.0M	26.4M	21.1M
Net Tangible Assets	640.5M	399.5M	1.3B	1.1B	1.3B	633.1M
Net Receivables	15.3M	25.4M	4.4M	2.2M	2.8M	2.7M
Retained Earnings Total Equity	(1.5B)	(1.8B)	(238.8M)	(470.6M)	(423.5M)	(444.7M)
Capital Surpluse	2.2B	2.2B	2.3B	2.4B	2.7B	1.7B
Inventory	7.3M	14.7M	16.2M	8.5M	19.1M	20.0M
Long Term Investments	152.9M	97.6M	266.4M	313.9M	29.4M	28.0M
Non Current Liabilities Other	157.3M	359.1M	85.9M	3.3M	1.2M	1.1M
Net Invested Capital	640.5M	399.5M	1.3B	1.1B	811.0M	833.9M
Net Working Capital	518.8M	542.3M	1.0B	770.1M	765.9M	702.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:

How To Invest In Agios

Details

Is Agios Stock a good investment?

Details

What is Agios Pharm's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Agios Stock analysis

When running Agios Pharm's price analysis, check to measure Agios Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharm is operating at the current time. Most of Agios Pharm's value examination focuses on studying past and present price action to predict the probability of Agios Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharm's price. Additionally, you may evaluate how the addition of Agios Pharm to your portfolios can decrease your overall portfolio volatility.

	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Global Correlations Find global opportunities by holding instruments from different markets
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Is Agios Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.31)

Revenue Per Share

0.526

Quarterly Revenue Growth

0.46

Return On Assets

(0.25)

Return On Equity

(0.40)

The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Agios Other Current Assets vs Total Liab Analysis

Other Current Assets vs Total Liab

Other Current Assets vs Total Liab Correlation Analysis

Correlation Coefficient

Other Current Assets

Total Liab

Agios Pharm fundamental ratios Correlations

Agios Pharm Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Agios Pharm fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Agios Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets

Cash	- 0.99	Net Debt
Retained Earnings	- 0.9	Other Current Liab
Other Stockholder Equity	- 0.86	Retained Earnings
Retained Earnings	- 0.83	Total Current Liabilities
Total Liab	- 0.82	Retained Earnings
Common Stock Shares Outstanding	- 0.8	Retained Earnings